Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BOLAR AND MYLAN TEAM TO PURCHASE SOMERSET LABS

Executive Summary

BOLAR AND MYLAN TEAM TO PURCHASE SOMERSET LABS objective is to provide the generic manufacturers with a source of proprietary pharmaceutical compounds and tie-in to a drug discovery and development capability. Terms of the cash deal, announced in-principle on Nov. 7, were not disclosed. Denville, New Jersey-based Somerset has at least one drug, Eldepryl (selegiline), pending FDA review. Granted a Treatment IND in June, the selective monamine oxidase B-type inhibitor is a potential adjuvant to levodopa in treating Parkinson's Disease. Eldepryl is one of three Somerset compounds originally developed by the Ungarian firm Chinoin. Ipriflavone, a non-hormonal therapy for osteoporosis, is currently in clinicals as is depogen, a hemorheologic agent for treatment of vascular disease. For Bolar, the agreement is the latest in a series of unusual joint ventures that have pushed the company into new product areas. Under an earlier agreement with Health-Chem's Hercon Labs, Bolar markets a transdermal nitroglycerin patch and is developing six other products with Hercon's proprietary transdermal delivery technology. In 1985, Bolar teamed with Agvar Chemical and former Elkins-Sinn exec Marvin Samson in establishing the generic injectables business Marsam Pharmaceuticals. Bolar's 1987 agreement with KV Pharmaceuticals covers the marketing of KV-developed sustained-release products. "Somerset also has the entree to future drugs being developed by a major foreign pharmaceutical company," a joint Bolar/Mylan press release states. The pharmaceutical division of S. C. Johnson before being spun off in 1985, Somerset also claims a strong working relationship with Gideon Richter, Semmelweis Medical University and the Hungarian Institute of Pharmaceutical Research.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS014590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel